Search

7th European CAR T-cell Meeting

The European Hematology Association (EHA) and the EBMT are excited to announce the 7th edition of the jointly organized European CAR T-cell Meeting.

Read more

I4MDS consortium: advancing MDS treatment and understanding

The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.

Read more

European Hematology Curriculum

Harmonization of hematology knowledge is part of EHA’s mission. The first step in harmonizing hematology training is to stipulate the required fields of knowledge, each with its recommended level of competence.

Read more

Previous winners, 2012–2022

2022 winners
Alexandre Fagnan
Junior Research Grant 2022
Deciphering the chromatin remodeling mechanism mediated by GATA2 ZnF1 mutations in AML

Samuele Ferrari
Junior Research Grant 2022
Innovative targeted base editing strategies for gene correction of WHIM syndrome

Lars Velten
Advanced Research Grant 2022
The role of the DNA methylation…

Read more

Selected EMA news

March 2025New medicines recommended for approval
Lynozyfic (linvoseltamab) 
Treatment of refractory multiple myeloma (a cancer of the bone marrow)
New information on approved medicines 
Calquence (acalabrutinib) - new indication
Treatment of blood cancer

Columvi (glofitamab) - new indication
Treatment of blood cancer

Darzalex (daratumumab) - change of indication
Treatment…

Read more

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more